Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients

Brachytherapy

Volumn 13, Issue 1, 2014, Pages 59-67

  Marina, Ovidiu ^a   Gustafson, Gary S ^a   Kestin, Larry L ^b   Brabbins, Donald S ^a   Chen, Peter Y ^a   Ye, Hong ^a   Martinez, Alvaro A ^b   Ghilezan, Michel I ^b   Wallace, Michelle ^a   Krauss, Daniel J ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b 21ST CENTURY ONCOLOGY   (United States)

Author keywords

Comparative outcomes; High dose rate brachytherapy; Image guided radiation therapy; IMRT; Prostate cancer

Indexed keywords

ADULT; AGED; ARTICLE; BRACHYTHERAPY; BRACHYTHERAPY IMPLANT; CANCER CONTROL; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CAUSE SPECIFIC SURVIVAL; COHORT ANALYSIS; COMPUTER ASSISTED RADIOTHERAPY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DOSIMETRY; FOLLOW UP; GLEASON SCORE; HUMAN; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; INTERMEDIATE RISK PATIENT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MIDDLE AGED; NONHUMAN; OVERALL SURVIVAL; PELVIS; PERINEURAL INVASION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TREATMENT OUTCOME; COMPARATIVE STUDY; MALE; PROCEDURES; PROSTATIC NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOTHERAPY, IMAGE-GUIDED; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84892540119     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2013.05.004     Document Type: Article

References (22)

1. Martinez A.A., Kestin L.L., Stromberg J.S., et al. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: The William Beaumont phase II dose-escalating trial. Int J Radiat Oncol Biol Phys 2000, 47:343-352.
2. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002, 52:6-13.
3. Kestin L.L., Martinez A.A., Stromberg J.S., et al. Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer. J Clin Oncol 2000, 18:2869-2880.
4. Sathya J.R., Davis I.R., Julian J.A., et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005, 23:1192-1199.
5. Deutsch I., Zelefsky M.J., Zhang Z., et al. Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. Brachytherapy 2010, 9:313-318.
6. Hoskin P.J., Rojas A.M., Bownes P.J., et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 2012, 103:217-222.
7. Cahlon O., Zelefsky M.J., Shippy A., et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008, 71:330-337.
8. Viani G.A., Stefano E.J., Afonso S.L. Higher-than-conventional radiation doses in localized prostate cancer treatment: A meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009, 74:1405-1418.
9. Zelefsky M.J., Yamada Y., Fuks Z., et al. Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008, 71:1028-1033.
10. Peeters S.T.H., Heemsbergen W.D., Koper P.C.M., et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006, 24:1990-1996.
11. Martinez A.A., Yan D., Lockman D., et al. Improvement in dose escalation using the process of adaptive radiotherapy combined with three-dimensional conformal or intensity-modulated beams for prostate cancer. Int J Radiat Oncol Biol Phys 2001, 50:1226-1234.
12. Martinez A.A., Gonzalez J., Ye H., et al. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 2011, 79:363-370.
13. Yan D., Lockman D., Brabbins D., et al. An off-line strategy for constructing a patient-specific planning target volume in adaptive treatment process for prostate cancer. Int J Radiat Oncol Biol Phys 2000, 48:289-302.
14. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974.
15. Bachand F., Martin A.-G., Beaulieu L., et al. An eight-year experience of HDR brachytherapy boost for localized prostate cancer: Biopsy and PSA outcome. Int J Radiat Oncol Biol Phys 2009, 73:679-684.
16. Huang J., Vicini F.A., Williams S.G., et al. Percentage of positive biopsy cores: A better risk stratification model for prostate cancer?. Int J Radiat Oncol Biol Phys 2012, 83:1141-1148.
17. Scrucca L., Santucci A., Aversa F. Regression modeling of competing risk using R: An in depth guide for clinicians. Bone Marrow Transplant 2010, 45:1388-1395.
18. Anderson P.R., Hanlon A.L., Patchefsky A., et al. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy. Int J Radiat Oncol Biol Phys 1998, 41:1087-1092.
19. Khor R., Duchesne G., Tai K.-H., et al. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer. Int J Radiat Oncol Biol Phys 2013, 85:679-685.
20. Demanes D.J., Rodriguez R.R., Schour L., et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 2005, 61:1306-1316.
21. Kotecha R., Yamada Y., Pei X., et al. Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer. Brachytherapy 2013, 12:44-49.
22. Chen W.C., Tokita K.M., Ravera J., et al. Four-year outcomes of hypofractionated high-dose-rate prostate brachytherapy and external beam radiotherapy. Brachytherapy 2013 Feb 1, [Epub ahead of print]. http://dx.doi.org/10.1016/j.brachy.2012.09.003.